Andrea wang gillam

Chief Medical Officer & Global Head of Research & Development Jacobio Pharmaceuticals Inc

Seminars

Tuesday 16th September 2025
Uncovering the Potential of a KRAS G12C Inhibitor in Combination of SHP2 Inhibitor for Treatment of NSCLC
9:00 am
  • Understanding the rationale of KRAS G12C plus SHP2 in NSCLC
  • Examining the preclinical data of this combination
  • Presenting the phase I/IIa results of the combination in NSCLC
Tuesday 16th September 2025
Panel Discussion: Identifying the Right Combination for Different Cancers by Tailoring RAS Inhibitors for Tumor-Specific Reponses
11:30 am
  • Overcoming the complexity of tumor biology and multiple signaling pathways to select the optimal combination approach for different cancer types
  • How can patient-specific genetic profiles and tumor microenvironment data inform the design of more effective combination therapies?
  • How do RAS inhibitors alter the tumor microenvironment and improve response to current standard of care cancer treatments?
Andrea Wang Gillam, Chief Medical Officer & Global Head of Research & Development, Jacobio Pharmaceuticals Inc